BAILEY HARVILLE: Open Payments
NPI 1346974250 · STATESBORO, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$766 in 47 payments from 13 companies in 2025. Trend: 2023 $1,362 · 2024 $1,081 · 2025 $766
Food & beverage: $766
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $193 |
| AstraZeneca Pharmaceuticals LP | 7 | $177 |
| Novo Nordisk Inc | 10 | $141 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $47 |
| Lundbeck LLC | 2 | $36 |
| PFIZER INC. | 2 | $36 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Abbott Laboratories | 1 | $18 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $17 |
Products named: VRAYLAR, AIRSUPRA, FARXIGA, Rybelsus, JARDIANCE, Ozempic, UBRELVY, REXULTI.
Industry payments across GA — which companies pay providers there.
